Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Vebreltinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vebreltinib is a targeted cancer capsule that blocks MET, a growth signal that some lung and brain tumours depend on. It was developed in China by Beijing Pearl Biotechnology (浦润奥), part of the Avistone group, and is sold there as 万比锐® enteric capsules. You may also see it called bozitinib, PLB-1001 or APL-101 in research papers.
China's National Medical Products Administration (NMPA) has approved it for three uses in adults:
A tumour test must first show the MET change. It is a prescription cancer medicine and should only be used under a medical oncologist or neuro-oncologist.
MET is a receptor on the cell surface. When a tumour carries a MET exon 14 skipping mutation, extra copies of the MET gene, or a MET fusion, that receptor stays switched on and keeps telling the cancer to grow. Vebreltinib is a highly selective MET tyrosine kinase inhibitor: it sits in the receptor's working pocket and shuts the signal off, which slows or shrinks tumours that rely on it.
In the phase 2 KUNPENG study, published in the Journal of Clinical Oncology in 2024, 52 people with MET exon 14 lung cancer took vebreltinib. Three in four (75%) had their tumours shrink, including 77.1% of those treated first-line and 70.6% of those treated before. Responses lasted a median of 15.9 months, the median time before the cancer grew again was 14.1 months, and median overall survival was 20.7 months.
A second KUNPENG group of 86 people with MET-amplified lung cancer, reported in The Lancet Oncology, had a response rate of 48.8%. In the FUGEN study in PTPRZ1-MET brain tumours, median survival was 6.31 months with vebreltinib against 3.38 months with chemotherapy.
Your oncologist sets the exact plan from the full Chinese prescribing information.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Swelling (oedema): this is the side effect most people notice. In the MET exon 14 trial, 82.7% had swelling of the legs, ankles or hands, and it was severe in 13.5%. Tell your doctor about rapid weight gain, tight shoes or puffiness, because the dose may need to be paused or reduced.
Overall: severe (grade 3 or higher) treatment-related side effects occurred in 48.1% of patients. 21.2% needed a lower dose, half had at least one pause in treatment, and 7.7% stopped. In the MET-amplified group, severe treatment-related side effects occurred in 31%. Safety in pregnancy, breastfeeding and children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other MET-targeted lung cancer options, see our pages on Tepmetko and Rybrevant.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The 100 mg enteric capsules travel in their sealed original packs under temperature-controlled shipping and should be stored as directed on the pack. At two capsules twice a day, a 28-day cycle uses 112 capsules, so we plan supply cycle by cycle to avoid gaps. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital on a valid specialist's prescription.
Thoracic oncology teams in Delhi often order MET testing on lung biopsies, and our New Delhi dispatch point keeps delivery times short.
Capsules can be sent straight to the treating hospital or to the patient's home, depending on what the oncologist prefers.
Oncologists here can request the medicine for a named patient once the MET report is available, with a written quote first.
A major cancer referral centre for South India, with experience in long-term oral targeted therapy.
We time each shipment so the next cycle arrives before the current supply runs out.
Patients in Kolkata and the eastern states receive sealed original packs with full import papers.
Families in Pune can use the same documented import route, with updates at every step.
The oncologist can share the prescription and molecular report with us to start the import.
Patients treated in Vellore, including those under neuro-oncology care, can have supply delivered to the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating centre.
We coordinate deliveries to cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive each month's capsules at their hospital in Kochi or nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
